Patent ID: 11944689
Assignee: SEAGEN INC.
Field: Pharmaceuticals (Chemistry)
Classification: CPC C  A | IPC A  C

Claim 20:
21. The Ligand Drug Conjugate compound of claim 1 wherein the Ligand Unit is an antibody Ligand Unit, thereby defining an antibody drug conjugate (ADC),
wherein the moiety targeted by the antibody Ligand Unit is an accessible cell-surface antigen of abnormal cells, wherein the targeted antigen is capable of cellular internalization of bound ADC and is present in greater copy number on the abnormal cells in comparison to normal cells distant from the site of the abnormal cells, or
wherein the targeted moiety of the antibody Ligand Unit is an accessible cell-surface antigen of a vascular epithelial cell in the vicinity of abnormal cells, wherein said antigen is capable of cellular internalization of bound ADC and is present in greater copy number on said cells in comparison to normal epithelial cells distant from the site of the abnormal cells.